Dr. Sankarganesh Arunachalams research focuses on Cardiovascular Adverse Drug Reactions. His primary interest is in understanding how the drug Doxorubicin leads to complications, particularly cardiomyopathy. This drugs clinical use is restricted due to its many adverse effects, including cardiomyopathy. Dr. Arunachalam discovered that Doxorubicin dysregulates the PPAR family, revealing new insights. His findings also indicate that Doxorubicin inhibits adipocyte differentiation, contributing to weight loss during chemotherapy. His team identified that PPARγ inhibition reduces adipose tissue, affecting spermatogenesis. Their research suggests that Doxorubicin induces a type 2 diabetic condition through adipose tissue inflammation. Dr. Arunachalams work explores two mechanisms: dysregulation of cardiac energetics and impairment of cardiac progenitor cells. His research has been supported by two grants from SERB, Government of India, and one from DST, Government of India.
